The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection

C da Cunha-Bang; N Kirkby; M Sønderholm; S S Sørensen; H Sengeløv; M Iversen; A Rasmussen; F Gustafsson; C M Frederiksen; J Kjaer; A Cozzi Lepri; J D Lundgren

doi:10.1111/ajt.12042

The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection

C da Cunha-Bang, N Kirkby, M Sønderholm, S S Sørensen, H Sengeløv, M Iversen, A Rasmussen, F Gustafsson, C M Frederiksen, J Kjaer, A Cozzi Lepri, J D Lundgren

Department of Immunology and Microbiology

16 Citations (Scopus)

Abstract

(Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004-2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC(50) ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio

Original language	English
Journal	American Journal of Transplantation (Online)
Volume	13
Issue number	2
Pages (from-to)	458-66
Number of pages	9
ISSN	1600-6143
DOIs	https://doi.org/10.1111/ajt.12042
Publication status	Published - Feb 2013

Keywords

Adult
Cytomegalovirus
Cytomegalovirus Infections
Drug Resistance, Viral
Female
Foscarnet
Ganciclovir
Hematopoietic Stem Cell Transplantation
Humans
Inhibitory Concentration 50
Male
Middle Aged
Mutation
Odds Ratio
Organ Transplantation
Phosphotransferases (Alcohol Group Acceptor)
Prevalence
Recurrence
Risk Factors
Time Factors
Treatment Outcome
Young Adult

Access to Document

10.1111/ajt.12042

Cite this

Cunha-Bang, C. D., Kirkby, N., Sønderholm, M., Sørensen, S. S., Sengeløv, H., Iversen, M., Rasmussen, A., Gustafsson, F., Frederiksen, C. M., Kjaer, J., Lepri, A. C., & Lundgren, J. D. (2013). The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. American Journal of Transplantation (Online), 13(2), 458-66. https://doi.org/10.1111/ajt.12042

Cunha-Bang, CD, Kirkby, N, Sønderholm, M, Sørensen, SS, Sengeløv, H, Iversen, M, Rasmussen, A, Gustafsson, F, Frederiksen, CM, Kjaer, J, Lepri, AC & Lundgren, JD 2013, 'The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection', American Journal of Transplantation (Online), vol. 13, no. 2, pp. 458-66. https://doi.org/10.1111/ajt.12042

@article{036923df5a3342c3a0077922e5ed038c,

title = "The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection",

abstract = "(Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004-2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC(50) ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio ",

keywords = "Adult, Cytomegalovirus, Cytomegalovirus Infections, Drug Resistance, Viral, Female, Foscarnet, Ganciclovir, Hematopoietic Stem Cell Transplantation, Humans, Inhibitory Concentration 50, Male, Middle Aged, Mutation, Odds Ratio, Organ Transplantation, Phosphotransferases (Alcohol Group Acceptor), Prevalence, Recurrence, Risk Factors, Time Factors, Treatment Outcome, Young Adult",

author = "Cunha-Bang, {C da} and N Kirkby and M S{\o}nderholm and S{\o}rensen, {S S} and H Sengel{\o}v and M Iversen and A Rasmussen and F Gustafsson and Frederiksen, {C M} and J Kjaer and Lepri, {A Cozzi} and Lundgren, {J D}",

year = "2013",

month = feb,

doi = "10.1111/ajt.12042",

language = "English",

volume = "13",

pages = "458--66",

journal = "American Journal of Transplantation (Online)",

issn = "1600-6143",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection

AU - Cunha-Bang, C da

AU - Kirkby, N

AU - Sønderholm, M

AU - Sørensen, S S

AU - Sengeløv, H

AU - Iversen, M

AU - Rasmussen, A

AU - Gustafsson, F

AU - Frederiksen, C M

AU - Kjaer, J

AU - Lepri, A Cozzi

AU - Lundgren, J D

PY - 2013/2

Y1 - 2013/2

N2 - (Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004-2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC(50) ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio

AB - (Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004-2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC(50) ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio

KW - Adult

KW - Cytomegalovirus

KW - Cytomegalovirus Infections

KW - Drug Resistance, Viral

KW - Female

KW - Foscarnet

KW - Ganciclovir

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Inhibitory Concentration 50

KW - Male

KW - Middle Aged

KW - Mutation

KW - Odds Ratio

KW - Organ Transplantation

KW - Phosphotransferases (Alcohol Group Acceptor)

KW - Prevalence

KW - Recurrence

KW - Risk Factors

KW - Time Factors

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1111/ajt.12042

DO - 10.1111/ajt.12042

M3 - Journal article

C2 - 23282281

SN - 1600-6143

VL - 13

SP - 458

EP - 466

JO - American Journal of Transplantation (Online)

JF - American Journal of Transplantation (Online)

IS - 2

ER -

The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection

Abstract

Keywords

Access to Document

Fingerprint

Cite this